Sign in
CompletedPhase 2

Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment

Key facts

Who runs it
Joseph Valentino, MD
Where
Bowling Green, Lexington, and Owensboro, United StatesSee the 3 sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
126 people enrolled
Started
12 Jan 2021
Ended
2 Jan 2026
Type of study
Interventional, 12 groups
Treatments tested
  • Varenicline
  • Bupropion
  • Long-acting nicotine replacement therapy
  • Low-intensity counseling
  • High-intensity counseling
  • No nicotine replacement therapy
  • Nicotine Replacement Products
Record updated
5 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • newly diagnosed or recurrent tobacco related malignancy
  • smoked at least 1 cigarette within 4 weeks of study enrollment
  • 10-pack year history of cigarette smoking
  • smoked at least 1 cigarette within 1 month of cancer diagnosis
  • life expectancy greater than 1 year

Who cannot take part

  • concurrent enrollment in tobacco cessation therapy
  • allergy to buproprion, varenicline and transdermal medicine
  • history of suicide attempt
  • hospitalized for psychiatric illness within past 2 years
  • history of active or uncontrolled eating disorder
  • uncontrolled epilepsy or seizure disorder
  • within 3 months of myocardial infarction
  • unstable angina
  • uncontrolled hypertension
  • serious arrhythmia
  • history of taking varenicline or buproprion within one month of enrollment
  • pregnant or lactating

Where in United States

  • Med Center HealthBowling Green, United States
  • University of Kentucky/Markey Cancer CenterLexington, United States
  • Owensboro Health Mitchell Memorial Cancer CenterOwensboro, United States

About the trial

What the trial wants to find out

Smoking cessation has been shown to improve the effectiveness and reduce the morbidity of tobacco-related cancer treatments. We will identify effective smoking cessation strategies for patients who are receiving treatment for tobacco-related cancer. In this trial, patients' preferences in smoking cessation therapy will be the principal determinant by providers in developing a three component regimen of pharmaceutical therapy, counseling, and nicotine replacement therapy. This study will identify this cohort's preferences for smoking cessation strategies. We will then examine the impact of utilizing patient preferences upon cessation efficacy by directly comparing cessation success in this study with our recently completed study of the same population using the same tobacco treatments which were randomly assigned.

The 12 groups in the trial

  • Group 1: Nicotine, Intense Counselling and NRTTreatment being tested

    Patients diagnosed with tobacco-related treatment will receive long acting nicotine replacement therapy (e.g. nicotine patch), counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.

    Treatment: Long-acting nicotine replacement therapy, High-intensity counseling, and Nicotine Replacement Products

  • Group 2: Buproprion, Intense Counselling and NRTTreatment being tested

    Patients diagnosed with tobacco-related treatment will receive Buproprion, counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.

    Treatment: Bupropion, High-intensity counseling, and Nicotine Replacement Products

  • Group 3: Varenicline, Intense Counselling and NRTTreatment being tested

    Patients diagnosed with tobacco-related treatment will receive varenicline, counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.

    Treatment: Varenicline, High-intensity counseling, and Nicotine Replacement Products

  • Group 4: Nicotine, Intense CounsellingTreatment being tested

    Patients diagnosed with tobacco-related treatment will receive long acting nicotine replacement therapy (e.g. nicotine patch) and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.

    Treatment: Long-acting nicotine replacement therapy, High-intensity counseling, and No nicotine replacement therapy

  • Group 5: Buproprion, Intense CounsellingTreatment being tested

    Patients diagnosed with tobacco-related treatment will receive Buproprion and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.

    Treatment: Bupropion, High-intensity counseling, and No nicotine replacement therapy

  • Group 6: Varenicline, Intense CounsellingTreatment being tested

    Patients diagnosed with tobacco-related treatment will receive varenicline and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.

    Treatment: Varenicline, High-intensity counseling, and No nicotine replacement therapy

  • Group 7: Nicotine, Minimal Counselling and NRTTreatment being tested

    Patients diagnosed with tobacco-related treatment will receive long acting nicotine replacement therapy (e.g. nicotine patch), counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.

    Treatment: Long-acting nicotine replacement therapy, Low-intensity counseling, and Nicotine Replacement Products

  • Group 8: Buproprion, Minimal Counselling and NRTTreatment being tested

    Patients diagnosed with tobacco-related treatment will receive Buproprion, counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.

    Treatment: Bupropion, Low-intensity counseling, and Nicotine Replacement Products

  • Group 9: Varenicline, Minimal Counselling and NRTTreatment being tested

    Patients diagnosed with tobacco-related treatment will receive varenicline, counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.

    Treatment: Varenicline, Low-intensity counseling, and Nicotine Replacement Products

  • Group 10: Nicotine, Minimal CounsellingTreatment being tested

    Patients diagnosed with tobacco-related treatment will receive long acting nicotine replacement therapy (e.g. nicotine patch) and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.

    Treatment: Long-acting nicotine replacement therapy, Low-intensity counseling, and No nicotine replacement therapy

  • Group 11: Buproprion, Minimal CounsellingTreatment being tested

    Patients diagnosed with tobacco-related treatment will receive Buproprion and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.

    Treatment: Bupropion, Low-intensity counseling, and No nicotine replacement therapy

  • Group 12: Varenicline, Minimal CounsellingTreatment being tested

    Patients diagnosed with tobacco-related treatment will receive varenicline and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.

    Treatment: Varenicline, Low-intensity counseling, and No nicotine replacement therapy

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
5 November 2026